Core Viewpoint - Four Seasons Pharmaceutical (00460.HK) announced that its non-wholly owned subsidiary, Xuan Zhu Biotechnology Co., Ltd. ("Xuan Zhu Bio"), will be included in the Hang Seng Composite Index, effective March 9, 2026, following the quarterly review results published by Hang Seng Indexes Company on February 13, 2026 [1] Group 1 - Xuan Zhu Bio is set to be listed on the Hong Kong Stock Exchange under stock code 2575 on October 15, 2025 [1] - The Hang Seng Composite Index covers the top 95% of listed companies on the Hong Kong Stock Exchange by market capitalization [1] - Inclusion in the Hang Seng Composite Index is expected to meet the eligibility criteria for the Stock Connect programs, which facilitate trading between Hong Kong and mainland Chinese investors [1]
四环医药(00460.HK)附属轩竹生物获纳入恒生综合指数成份股